copenhagen denmark, August 22, 2022 /PRNewswire/ — The BioInnovation Institute (BII), an international for-profit, non-profit foundation fostering and accelerating world-class life sciences research, today announces investments in three international UK start-ups Did. GermanyWhen FinlandThe three new ventures are strategically aligned with BII’s focus to develop groundbreaking scientific initiatives across the therapeutic and healthtech sectors.

Each of these companies will be financed with a risk-free convertible loan. 1.3 million euros You will also be part of BII’s life sciences startup community. In collaboration with the BII team and its network of experts, companies are guided to a competitive international level and supported in developing detailed development plans for drug development, good manufacturing practices and regulatory strategies prior to seed or series. receive. funding round.

Commenting on today’s launch, Bobby SoniChief Business Officer of the BioInnovation Institute, said:: “Our goal is to harness the untapped potential of European research.At BII, we help each venture overcome potential hurdles and position itself to attract top quality international investment. Spin outs from the best translational research environments around the world Europe, VEIL.AI, Myopax and Sevenless Therapeutics each have great potential in the field of therapeutic and health technology. We are happy to support their growth by supporting business acceleration, scientific and team development. ”

New ventures include:

• Sevenless Therapeutics is a next generation biotechnology company. Sevenless Therapeutics used state-of-the-art mathematical methodology to identify novel targets of pain signaling, define drug properties required for success, and validate these predictions with data. With this insight, our experienced drug discovery team efficiently delivers safe and effective drug candidates to treat pain. This finding will make a big difference for many patients suffering from chronic pain that is undertreated.
• VEIL.AI takes the quality of anonymized health data to a new level with next-generation anonymization technology, creating extremely high quality subject-level anonymized and synthetic data. This will enable Life’s science and diagnostics companies, hospitals, and his medical data hub to make better use of his GDPR-free data.
• Myopax holds proprietary muscle stem cell technology for advanced regenerative therapies to combat the devastating consequences of muscle disease.Spin-off stems from the translation ecosystem BerlinCharité University, Max Delbrück Center for Molecular Medicine of the Helmholtz Society, Berlin Institute for Hygiene.

BII has supported 62 start-ups €50 million Funding in progress. BII start-ups total €207 million from domestic and foreign investors. Its diverse team brings together venture capital, pharmaceutical and business expertise to help early stage companies accelerate to the next level. Recent successes include Adcendo, Stipe Therapeutics, Twelve Bio, Octarine Bio and Cirqle Biomedical.

Read more at https://bii.dk/start-ups/

About Bio Innovation Research Institute Foundation

The BioInnovation Institute Foundation (BII) is a non-profit international commercial foundation supported by the Novo Nordisk Foundation. BII operates an incubator to accelerate world-class life science innovation, driving early life science start-ups to develop new solutions for the benefit of people and society.

BII, Location copenhagen denmark, healthtech, therapeutics and bioindustry cutting-edge laboratories, vibrant office facilities, business development, start-up incubation, high-level mentoring and access to international networks to host start-ups and early-stage projects. Offers.Plus the largest and unique fundraising opportunities 1.3 million euros per startup 2.4 million euros per project.

Since the launch of BII November 2018BII awarded €50 million 62 high-growth start-ups. For more information, please visit www.bioinnovationinstitute.com.

Source Bioinnovation Institute (BII)